A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Breast cancer; Gastric cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms MEDIOLA
- Sponsors AstraZeneca
- 13 Jun 2017 Planned End Date changed from 4 Sep 2018 to 27 Jul 2018.
- 13 Jun 2017 Planned primary completion date changed from 4 Sep 2018 to 27 Jul 2018.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.